PSUN276 GLP1RAs use for treating NALFD in a multidisciplinary clinic in low socioeconomic community

: GLP1RAs have been proven beneficial for weight loss in patients with NAFLD with or without Diabetes. However, such use is limited due to cost and limited insurance coverage in those without diabetes. Method: Retrospective chart review of patients with NAFLD seen at Multidisciplinary NAFLD clinic in Low SES community Result: A total of 11 patients (55% Female, mean age 49.2±13.8 yrs, BMI 39.3±7.8 kg/m2) diagnosed with NAFLD were seen by hepatologist, endocrinologist and dietician and instructed and counseled for lifestyle modification aiming for at least 5% weight loss within 6 months. Five had diabetes with A1C 6.7% to 8.3%, and the remaining had Pre-Diabetes. Semaglutide 1 mg weekly SC was used in 8 patients (72.3%), liraglutide 3 mg qd in 1 patient, metformin in 1 patient, generic phentermine topiramate in 1 patient. Initial data of SBP(mean 129±9.0 mmHg), LDL (mean 97.8±31.6 mmol/L), TAGs (mean 193.6±109.6 mg/dl), AST (mean 43.5±21.8 U/L), and ALT (mean 50.8±25.9 U/L) were collected and followed at 6 and 12 months. Among 8 patients with complete 1 year data, all except one (87.5%) achieved weight loss goal at least 5% at 6 and 12 months. Among Five patients with greatest weight lost 14-20% at 1 year with significant improvement in metabolic panels, 80% of them were on GLP1RA. At 6 months and 12 months mean SBP was 125.3±5.8 and 123.9±10.3 mmHg, mean LDL was 75.5±16.4 and 71.4±21.2 mmol/L, mean TAGs was 161.2±114.5 and 158.7±90.9 mg/dl, mean AST was 19.4±4.0 and 19.4±4.5 U/l, and mean ALT was 26.7±8.3 and 33±16.1 U/L respectively. CONCLUSION: In this case series from our multidisciplinary NAFLD clinic, we observed the achievement of weight loss goal and improved clinical parameters by 12 months. The clinic can be beneficial in low SES community. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m.